Fig. 2
From: Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
Distribution of other biologics used at baseline excluding infliximab. Adalimumab was more frequently used across groups. *Others included anakinra, belimumab, canakinumab, golimumab, ixekizumab, rituximab, sarilumab, secukinumab, tocilizumab, and ustekinumab